Harvard researchers develop multiregional brain-on-a-chip
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
List view / Grid view
News
Non-invasive screening method shows properties of pills
Information on significant properties of pharmaceutical tablets, such as their mechanical strength and dissolution, can now be obtained without resorting to the conventional, time-consuming and destructive testing methods, according to a new study completed at the University of Eastern Finland.
Amgen and Immatics to collaborate on bispecific cancer immunotherapies
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
IDBS launches E-WorkBook Cloud to manage scientific and R&D data
IDBS has launched the E-WorkBook Cloud, an enterprise, Cloud-based platform designed specifically to meet the future challenges of scientific and R&D data management.
Takeda to acquire ARIAD Pharmaceuticals
The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017.
Researchers find a potential target for anti-Alzheimer treatments
The USP9 gene has an indirect influence on the so-called tau protein, which is believed to play a significant role in the onset of Alzheimer’s disease.
Latest revision on FDA combination product guidance presented at Pre-Filled Syringes Boston Summit
FDA Present on Regulatory Considerations for Combination Products at Pre-Filled Syringes East Coast this Spring...
BenevolentAI becomes first AI company to appoint a Chief Medical Officer
BenevolentAI is the first AI company to have a CMO on its staff.
Chronos and Aptuit partner up for addictive behaviour programmes
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
Macrophage raises £9 million & acquires immune-oncology technology
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
Ottoline Leyser wins 2017 FEBS EMBO Women in Science Award
This award recognises outstanding achievements of female researchers in the life sciences in the past five years.
Kymab receives $9m R+D grant from Bill & Melinda Gates Foundation
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
Global partnership launched to enable personalised therapies in multiple sclerosis
In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
Immunotherapy and gene therapy combination shows promise against brain tumours
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
Chance meeting leads to creation of antibiotic spider silk
An team of scientists at the University of Nottingham has developed a technique to produce chemically functional spider silk that can be tailored to applications used in drug delivery, regenerative medicine and wound healing.